Table 2.
Relative risk of severe infectious events with EGFR-MoAbs according to tumor types, EGFR-MoAbs, concomitant therapies and phases of trials
| Groups | Studies, number | Severe infectious events, number/total, number | RR (95%CI) | P value | P value for group difference | |
|---|---|---|---|---|---|---|
| EGFR-MoAbs | Control | |||||
| Tumor types | ||||||
| CRC | 11 | 276/3801 | 181/3808 | 1.42 (1.05 to 1.93) | 0.024 | 0.001 |
| NSCLC | 7 | 199/1341 | 137/1344 | 1.45 (1.19 to 1.77) | <0.001 | |
| Head and neck cancer | 4 | 64/810 | 43/810 | 1.48 (1.02 to 2.13) | 0.037 | |
| Others | 4 | 62/494 | 77/397 | 0.72 (0.53 to 0.97) | 0.033 | |
| Anti-EGFR MoAbs | ||||||
| Cetuximab | 21 | 467/4548 | 299/4465 | 1.52 (1.33 to 1.75) | <0.001 | 0.092 |
| Panitumumab | 5 | 134/1898 | 139/1894 | 0.99 (0.62 to 1.60) | 0.98 | |
| Concomitant therapies | ||||||
| Cisplatin | 8 | 233/1690 | 148/1608 | 1.48 (1.22 to 1.79) | <0.001 | 0.30 |
| Irinotecan | 4 | 100/942 | 68/999 | 1.53 (1.12 to 2.10) | 0.008 | |
| Oxaliplatin | 8 | 192/2892 | 172/2847 | 0.97 (0.58 to 1.61) | 0.90 | |
| Radiotherapy | 3 | 13/312 | 11/313 | 0.99 (0.47 to 2.10) | 0.98 | |
| Others | 3 | 73/610 | 39/592 | 1.80 (1.24 to 2.62) | 0.002 | |
| Phases of trials | ||||||
| Phase II | 9 | 35/514 | 21/422 | 1.26 (0.75 to 2.12) | 0.39 | 0.82 |
| Phase III | 17 | 566/5932 | 417/593 | 1.34 (1.08 to 1.67) | 0.008 | |
| Overall | 26 | 601/6446 | 438/6359 | 1.34 (1.10 to 1.62) | 0.003 | NA |
CI, confidence interval; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; NA, not available; NSCLC, non-small-cell lung cancer; RR, relative risk.